Trial Profile

CLADQoL: CLADribine tablets –evaluation of Quality of Life - CLADQoL

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cladribine (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms CLADQoL
Sponsors Merck Serono

Most Recent Events

17 Sep 2025 According to an EMD Serono media release, data fromthis study presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in Barcelona.
02 Nov 2020 Status changed from recruiting to active, no longer recruiting.
01 May 2020 Results (n=67) presented at the 72nd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com